Beat COVID-19 - Observational Trial

COVID-19 Clinical Trial

— JUPITER  

Official title:

A Virtual Observational Protocol to Gain Longitudinal Data in Participants to Help Understand COVID-19 Spread and Disease Progression

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT04337762
• Other study ID #: 20200835
• Status: Recruiting
• Start date: April 6, 2020
• Est. completion date: July 2021

Study information

• Verified date: April 2020
• Source: Beat COVID LLC
• Contact: Rama Jager, M.D.
• Phone: (708) 620-4608
• Email: rjager[@]beatcovidtrial.com
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

JUPITER is an observational study protocol that aims to understand factors that can help prevent/mitigate the spread of COVID-19 and understand factors that help reduce disease progression in patients with COVID-19. We aim to accomplish this by obtaining self-reported historical and longitudinal data from study participants.

Description:

This is an observational study that will electronically collect self-reported participant data in a database that follows HIPAA security requirements for those with a clinically confirmed case of COVID-19 or those who have had exposure to COVID-19.

The aim of this study is to gather a large, diverse dataset from a large population of participants in order to gather longitudinal observational data on what health practices participants are practicing and what, if any, benefits these practices may be providing the participants.

Data for this study will be gathered via self-reporting from participants who wish to participate in the fight against COVID-19. This will include getting a baseline of each participant's health and then monitor their health over time while looking at how their symptoms are progressing or regressing. The JUPITER study may also seek historical data from patients who have recovered from COVID-19.

The JUPITER dataset may be shared (in accordance with applicable state, federal, and local laws) so that others may utilize the data from the dataset for further analysis to determine relevant trends in the data and in turn hopefully use these trends to determine potential treatment protocols or lifestyle recommendations to help prevent COVID-19 spread and reduce hospitalization rates, as well as to understand how certain factors may aide in the COVID-19 disease progression.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 100000
• Est. completion date: July 2021
• Est. primary completion date: December 2020
• Gender: All
• Age group: 18 Years to 110 Years

Eligibility

Inclusion Criteria:

1. Adults residing in the United States aged 18 years or older proficient in understanding and reading the English language who wish to participate in the fight against COVID-19 by providing self-reported health information.

2. Ability to complete electronic informed consent process.

3. Ability to use the internet and check email regularly.

4. Consent to provide a HIPAA waiver of health information to share protected health information.

Exclusion Criteria:

1. Inability to provide regular updates to their health status when contacted by the BEAT COVID study personnel via email or SMS.

Related Conditions & MeSH terms

• COVID-19

Locations

Country	Name	City	State
United States	Beat COIVD, LLC	Chicago	Illinois

Sponsors (1)

Lead Sponsor	Collaborator
Beat COVID LLC

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Health Outcomes	Patterns of data will be mined to understand risks for hospitalization and disease progression associated with COVID-19	1 year